HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα, respectively As previously ...
Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart and elebsiran, a combination therapy developed for chronic Hepatitis B in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback